Ibritumomab tiuxetan (TP-106CL)
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
Specifications
- Classify
- Protein therapeutics that deliver other compounds or proteins
- Therapeutic
- Ibritumomab tiuxetan
- Trade Name
- Zevalin
- Function
- A mAb portion that recognizes CD20+ B cells and induces apoptosis while the chelation site allows either imaging (In-111) or cellular damage by beta emission (Y-90)
- Examples of Clinical Use
- Relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma (NHL), including rituximab-refractory follicular NHL
References
- Synonyms
- Ibritumomab, mAb Murine (IGG1) Anti P19437 (CD20_MOUSE)
- UniProt
- P01865
- Genbank
- J00470
For lab research use only, not for diagnostic, therapeutic or any in vivo human use.
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
Tel: 1-631-381-2994
Fax: 1-631-207-8356
Email: